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Abstract Most kidney cancers are renal cell carcinomas
(RCC). RCC lacks early warning signs and 70 % of
patients with RCC develop metastases. Among them, 50 %
of patients having skeletal metastases developed a dismal
survival of less than 10 % at 5 years. Therefore, exploring
the key driving proteins and pathways involved in RCC
bone metastasis could benefit patients’ therapy and prolong
their survival. We examined the difference between the
OS-RC-2 cells and the OS-RC-2-BM5 cells (subpopulation
from OS-RC-2) of RCC with proteomics. Then we
employed Western-blot, immunohistochemistry and the
clinical database (oncomine) to screen and verify the key
proteins and then we analyzed the functions and the related
pathways of selected key proteins with system biology
approaches. Our proteomic data revealed 26 significant
changed spots (fold change \0.5 and [1.9, P\ 0.05)
between two cells. The Western blotting results validated
for these identified spots were consistent with the pro-
teomics’. From the public clinical database, 23 out of 26
proteins were connected with RCC metastases and 9 out of
23 with survival time directly (P\ 0.05). Finally, only 8
out of 9 proteins had significantly positive results in tissues
of RCC patients with bone metastasis compared with pri-
mary tumor (P\ 0.05). System biology analyzing results
showed these eight proteins mainly distributed in oxidative
phosphorylation which indicates that mitochondria dys-
function played the critical role to regulate cells metastasis.
Our article used a variety of experimental techniques to
find eight proteins which abnormally regulated mitochon-
drial function to achieve a successful induction for RCC
metastasis to bone.
Keywords Renal cell carcinoma  Bone metastasis 
Mitochondria dysfunction  System biology  Proteomics
Introduction
In adults, renal cell carcinoma (RCC) is the most common
type of kidney cancer, responsible for approximately
80–85 % of cases [1]. Around 270,000 cases of kidney
cancer are diagnosed yearly and 116,000 people die from
the disease in the world. Approximately 90 % of all kidney
cancers are RCC [2]. RCC is characterized by a lack of
early warning signs, which results in a high proportion of
patients with metastases [3] and it is a common group
relatively resistant to radiation therapy and chemotherapy
as well. 70 % of patients with RCC develop metastases
during the course of their disease and patients with meta-
static RCC have a dismal survival of less than 10 % at
5 years [4, 5]. Among them, approximately 50 % of
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patients with metastatic RCC have skeletal related diseases
development and more than 35 % dying with RCC have
skeletal metastases [5]. Patients with bone destruction from
metastatic RCC often have devastating complications
including pain, impending or actual fractures, is neurologic
compromise from spinal lesions, anemia, and complica-
tions exacerbated by immobilization such as hypercalcemia
[6]. Currently, the incidence of RCC is increasing but the
mortality rate has not improved significantly, most likely
because currently available therapies for bone metastatic
disease have little efficacy [6–8]. Thus, bone metastasis in
RCC is one of the major causes of increased morbidity and
eventual mortality and it is the future focus for therapy to
RCC patients as well. Now, the priority is to find the key
driving proteins for RCC with bone metastasis, which plays
the key roles in improving for RCC with bone metastasis
patients’ prognosis and developing preventive/therapeutic
strategies.
Previously we established the bone-seeking (ACHN-
BO) subpopulation from the human RCC cell line ACHN
in nude mice. We already showed the phenotypic changes
from ACHN parental cells (ACHN-P) to bone-seeking
(ACHN-BO) that could be a reason for RCC cells to
develop and accelerate bone metastases. However, the
molecular mechanisms are not fully understood [9]. To
fully explore the pathogenesis of RCC bone metastasis, we
use another RCC cell line OS-RC-2 to develop the animal
model like before, which has higher incidence of bone
metastases and shorter tumorigenic time according to our
previous method with a little variation [9] (Fig. 1c). We
also established the bone-seeking cell clones (OS-RC-2-
BO5). After investigating the proliferation and invasion
between the OS-RC-2-BM5 and OS-RC-2 cells, we com-
pared the expression of proteins between these two groups
cell by 2D gel electrophoresis (2-DE) and got the 100
different protein expressions. Among these proteins, 26
significant changes proteins which involve 3 down-regu-
lated and 23 up-regulated were selected. We checked the
clinical relevance of these 26 proteins from the public
clinical data (www.oncomine.com) and RCC patients’ tis-
sues. Finally we selected 8 proteins that most probably play
an indispensable role for bone metastasis of RCC.
For a better understanding the interaction, function of
these eight proteins and related pathway involved, we
employed the system biological approaches to analyze
them and surprisingly found these 8 proteins are most
likely to induce RCC bone metastases by abnormally reg-
ulating the mitochondrial function.
In this article, we used a variety of experimental tech-
niques, from animal models to cellular and molecular
levels, from in vitro to in vivo and combining with the
clinical data, to confirm that 8 proteins screened from 2-DE
were pretty active in the formation of RCC bone
metastases. Furthermore, we utilized system biology
approaches to analyze the proteins’ function, protein–pro-
tein interaction (PPI) and signaling pathway to confirm the
mitochondria dysfunction may play a critical role for
metastasis, which may shed light on the clinical therapies
for bone metastases of RCC patients.
Materials and methods
Cells and animals
OS-RC-2 cells, a human renal cancer line, were obtained
from China Center of Type Culture Collection (CCTCC),
Wuhan (China). For selection in vivo, 5–8 weeks old nude
mice (BALB/c-nu) were obtained from the Experimental
Animal Center of Huazhong University of Science and
Technology (Wuhan, China). All animals were housed
under pathogen-free conditions and maintained according
to the guidelines of the Committee on Animals of Huaz-
hong University of Science and Technology.
Cell growth, invasion and cell cycle assay
Cell growth and invasion assay were detected with MTT
and Trans-well migration assay (Corning). The flow
cytometry was used to detect the cell cycle. All the
experimental procedures can be found in [9].
In vivo selection of OS-RC-2-BM5
The detailed experimental methods can be seen in previous
publications [10]. Here, in brief, nude mice were anes-
thetized and injected into the left ventricle with 0.1 ml of
OS-RC-2 cells (1 9 106 cells). The osteolytic lesions in
limbs were detected by radiography (every 1–2 days
starting from the beginning) and after sacrificing, the
affected limbs were separated from the body. Tumor cell
suspension was collected. These subpopulations (OS-RC-
cFig. 1 a The osteolytic lesion taken by X-ray shown from from 4th to
7th week in nude mice tibias. b The tumor sizes of bone metastasis
measured by vernier caliper from 4th to 7th week. c Kaplan–Meier
curves showing the bone metastases activity of the parental
(ATCC)ACHN and OS-RC-2 cells population, various in vivo
selected subpopulations. Metastasis was scored as the time to first
appearance of a visible bone lesion by X-ray imaging. d The volume
data showed as column chart. Tumor volume was calculated by
formula: volume = (width)2 9 length/2. e Is Micro-CT examination
for mice legs with bone metastasis, after fixed by 4 % buffered
formalin. f The images of haematoxylin and eosin (HE) staining on
bone metastasis lesions. The original magnification is 940 and 9200.
Asterisk means there is a significant difference between 6th or 7th
week and 5th week (P\ 0.05)
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2-BM) were again inoculated into the left heart ventricle.
Following five passages of in vivo selection, a highly bone
metastatic cell line, OS-RC-2-BM5, was obtained for fur-
ther experiments. All animal experiments were approved
by the Tongji Hospital affiliated Huazhong University
Animal Ethics Committee.
Radiological and micro-computed tomography
analysis of osteolytic lesions and samples histology
Using a Digital Faxitron small animal X-ray cabinet
(Faxitron X-Ray, Wheeling, IL, USA) at 35 kV tube
voltage, 0.3 mA current and 4 s exposure time, Osteolytic
lesions in limbs were monitored. The image analysis
software (Analysis Software Imaging System GmbH,
Germany) was used to quantify the lesion area in limbs.
The lCT system is a cone beam tomograph (Scanco
Medical, Switzerland) with a microfocus X-ray tube pro-
viding a 10-lm focal spot. 3D-image surface reconstruc-
tions were performed using the lCT software. Additional
sagittal view of tibial lesion were performed on a desktop
computer using customized software for image analysis
[11, 12]. The tissue sections of 4 lm thick were cut and
stained with hematoxylin and eosin (H&E) and standard
protocols were used as before [9]. Samples and tissue
sections from patients were observed by immunohisto-
chemistry and stained with DAB [13]. The primary anti-
bodies resource can be seen in Supplementary 4 (Table 2).
Protein preparation
After removing the culture medium from the cells, the
adherent cells were washed once with PBS followed by an
additional short rinsing with ice-cold double distilled H2O
to remove remaining proteins. The tissue culture dish was
quickly frozen with liquid nitrogen, which was allowed to
warm up to room temperature and 1 ml lysis buffer and
was added with PMSF protease inhibitor (Thermo scientific
and Sigma-Aldrich Co). Transferred suspension to fresh
tubes, frozen with liquid nitrogen and sonicated in an ice-
cold ultrasonic bath for 30 min. Subsequently, the lysate
was centrifuged at 13,000 rpm for 5 min at 4 C. 2-D
Quant Kit (GE Healthcare, USA) was used to measure the
protein content of supernatant.
Two-dimensional gel electrophoresis (2DE)
Protein samples, 150 mg for silver-stained gels and
500 mg for colloidal Coomassie-stained gels, were pre-
cipitated and resuspended. The samples experienced
rehydrated and followed by the IEF procedure on 24 cm
non-linear immobilized gradient strips (GE Healthcare).
Electro focusing was carried out. Next, proteins were
reduced at 20 C for 20 min and followed by alkylation.
The second dimension was carried out on SDS PAGE gels
and 8 W/gel at 15 C. After fixed, analytical gels were
stained using silver nitrate. [14].
Spot detection and quantitation
The Delta 2D software version 4.0 (Decodon company)
was used to evaluate the Gel. A spot detection was per-
formed with the Delta 2D software for the fused image of
all time points [15]. Spot intensities were firmed and nor-
malized. The more details can be seen [16].
Western blot analysis
Equal quantities of protein were processed for Western
blotting [17]. Each sample was denatured, electrophoresed,
and transferred onto a PVDF membrane. After blocking the
membrane, blots firstly were incubated in specific anti-
bodies and then secondary antibodies following the man-
ufacturer’s instructions. The results of Western blot were
quantified with Gene Snap soft-ware (Syngene, America).
The primary antibodies were listed at Supplementary 4
(Table 2).
Clinical pathological assessment
Totally, 57 patients’ samples were used to analyze
expressions of screened proteins. Among them, 14 cases
are normal kidney, 16 cases are from primary RCC and 27
samples are derived from bone metastasis lesions of RCC
patients. All samples were gotten from tissues of surgical
resection from Tongji Hospital of Wuhan China between
March 2001 and December 2013. The methods of fixation,
decalcification, section and staining were followed as
above using common protocols. The informed consent was
obtained from all individual participants included in this
study.
System biology approach
The public clinical database was from Oncomine V4.5. The
proteins’ function, protein–protein interaction (PPI) and
related pathway analysis relied on IPA (Ingenuity),
STRING and DAVID (gene function classification tool).
Statistical methods
All statistical data in the samples were showed as
mean ± SD. Statistical analysis was performed using SPSS
13.0 (SPSS, USA). T test was used to compare the differ-
ence between two samples. In Kaplan–Meier curves, the
discrepancy between two samples was compared with Chi
608 Clin Exp Metastasis (2015) 32:605–622
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square test. Differences were considered to be statistically
significant when the P value was\0.05.
Results
The establishment of OS-RC-2-BM
In the first cycle of inoculation, 13.33 % (4/30) of the trans-
planted nude mice with OS-RC-2cells inoculated through the
left ventricle had tumor clones in bone and lung. The remaining
26.67 %(8/30) showed lungmetastasis alone and60 %(18/30)
of the transplanted mice were observed for 10 weeks without
bone and other organs’metastasis and tumor-related death. The
bone metastasis tumor clones were dissected and used for
culture. In the second cycle, 20 % (6/30) of mice had bone
metastasis and 40 % (12/30) mice appeared both skeleton and
lung metastasis. We continued to repeat the experiments by
injecting mice with higher chance of bone-metastasis cells.
Until the fifth cycle, the highest percentage of bone metastasis
in the transplanted mice was observed, 53.33 % (16/30). Most
of the bone metastasis sites were spine and the four limbs. We
named the fifth cycled bone metastasis cells as OS-RC-2-BM5
with histological analysis confirmation.
Most animals developed aggressive osteolytic bone
metastasis monitored by radiography (Fig. 1a). The tumor
sizes were also measured by caliper (Fig. 1b). The inci-
dence of bone metastasis by parental OS-RC-2 and OS-RC-
2-BM5 cells compared with ACHN cells in Fig. 1c. Tumor
volume was calculated with results shown in Fig. 1d [18].
At the 6th and 7th week, tumor volume significantly
increased to 118.32 ± 5.87 and 140.92 ± 9.716 mm3
compared with 5th week (P\ 0.05). Parts of legs were sent
to micro-CT (Fig. 1e) examination. In addition, parts of
tumor mass were processed into (HE) staining (Fig. 1f),
which showed the destruction of bone tissue and a large
group of tumor cells gathering at the site of osteolysis. The
results from radiography, micro-CT and H&E histology
examination tell us that the OS-RC-2-BM5 cells derived
from renal cancer cell lines because of clear cell mor-
phology and more characteristic for bone-seeking than OS-
RC-2 cells, which also caused bone tissue swollen, reduced
trabecular, thin bone cortical and mainly with osteolytic
destruction. The observed extensive bone destruction was
similar to those noted in clinical settings which mainly
occurred in cancellous bone like side of tibia and femur,
Spine and even pelvis in RCC patients with metastasis.
The proliferation and invasion of OS-RC-2-BM5 cell
line in vitro
First of all, we used Trans-well invasion assay to investi-
gate the invasive ability of OS-RC-2 and OS-RC-2-BM5
cell lines. After 16 h, we washed the top matrigel and
stained the penetrated cells as seen in Fig. 2a. There are
more OS-RC-2-BM5 went through the matrigel than OS-
RC-2 (P\ 0.05) in Fig. 2b. Next, we tested the cell pro-
liferation by MTT assay. Data from 24, 48, 72, 96, 120 h
time point were collected for proliferation curve. The more
quickly proliferation in OS-RC-2-BM5 cells was observed
than OS-RC-2-P cells (Fig. 2c). In addition, the results from
flow cytometry treated with propidium iodide (PI) showed
us the proportions of two cells in S stage and G2/M stage
was notably different. There are 13.32 ± 1.56 % OS-RC-2
cells on S phase plus G2/M phase, but 24.31 ± 2.13 % OS-
RC-2-BM5 cells on S phase and G2/M phase in Fig. 2d, e,
which means the more OS-RC-2-BM5 cells in proliferation
stage.
2-DE results and Western blot verification
In our study, crude proteins were extracted from OS-RC-2
and OS-RC-2-BM5 cells separately. More than 800 protein
spots were detected and 100 altered spots displayed dif-
ferentiation. The differences in spot intensities between
two cells were analyzed in Fig. 3a. Among them, 25 pro-
tein spots (P\ 0.05) were noticeably down-regulated and
75 protein spots (P\ 0.05) were noticeably up-regulated in
the OS-RC-2-BM5 on the right panel (Fig. 3a). 4 of 25
protein spots were down-regulated with fold change\0.5
and 26 of 75 spots were up-regulated with fold change
[1.9. After further analysis to exclude the replicate iden-
tifications, the final identification of 3 down-regulated and
23 up-regulated proteins were allowed. All of the protein
spots were successfully identified with confidence inter-
val % (CI %) values[95 % and the matched proteins were
obtained from the IPI database. The description on 3 ? 23
proteins can be seen in Supplementary 5 (Table 3). The
positions of identified spots are displayed by accession
numbers on a fused gel image in Fig. 3a.
To validate the results of the proteomics analysis,
quantitative Western blot assay were performed for 26
proteins. The alteration of proteomics and Western blot
analysis of 26 proteins in two cells: The magnified images
of protein spots from the 2-DE gels were shown on the
upper and the Western blot replicate results list below. The
line charts show the protein levels based on 2-DE and
Western blot results (Fig. 3b). The comparison of Western
blot with those of proteomics screening shows the corre-
sponding protein expressions, which validated our pro-
teomics screening method.
Genes expression and patients prognosis
We next searched these genes/proteins expression in public
clinical datasets to see whether expressions of genes have






























Fig. 2 a The transwell migration assay to investigate the invasive
ability of OS-RC-2-P and OS-RC-2-BM5 cells after 16 h incubation.
b The number of transmembrane cells for OS-RC-2-P and OS-RC-2-
BM5 cells showed as column chart. Asterisk means the transmem-
brane number of OS-RC-2-BM5 cells is pretty higher, comparing to
OS-RC-2 cells, P\ 0.05. c The proliferation curve which was got by
MTT assay at time point 24, 48, 72, 96, 120 h respectively. d The
flow cytometry analyzing cell cycle. e Comparison of cell cycles on
two cell lines
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any clinical relevance. TCGA Renal2, etc. 6 database were
employed. TCGA Renal2 dataset including the maximum
sample size were used for evaluation of prognosis. Results
showed 23 out of 26 genes expressed higher in RCC
patients with M1 than M0 (P\ 0.05), originated in at least
one database (Supplementary 2). 8 out of 23 genes
(EEF1D, EZR, HNRNPK, HPCAL1, SET, SLC9A3R1,
VCP and NDUFS1) showed this trend even in more than
two databases. Additionally, these 8 genes also showed
consistent trend: enhanced expression abided by rising
tumor stages and grades. From Kaplan–Meier curve
(Fig. 4), 9 out of 23 genes/proteins significantly affected
survival time of RCC patients. Here, the K–M curves
showed that Patients with EEF1D, NDUFS1, HPCAL1,
EZR, SLC9A3R1, HSP90B1 genes low expression can
survive longer than those with high expression. Con-
versely, the patients with high level VCP, SET and
HNRNPK had a better prognosis.
Generally, high expression of the gene in patients with
Metastasis indicates poor prognosis. Curiously, VCP, SET
A 
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OS-RC-2-BM5 OS-RC-2-BM5 OS-RC-2 

















Fold in western blot
Fold in protemic
Fold in western blot
Fig. 3 a The 2-DE gel showing the different spot intensities between
OS-RC-2 and OS-RC-2-BM5. Among these altered proteins, 25
protein spots (P\ 0.05) were noticeably down-regulated in the OS-
RC-2-BM5 group (middle panel) and 75 protein spots (P\ 0.05)
were significantly up-regulated in the OS-RC-2-BM5 group on the
right panel. b Results of quantitative Western blotting experiments
performed for 26 proteins (change fold \0.5 and [1.9). The
magnified images of protein spots from the 2-DE gels were shown
on the upper part of each panel and the Western blot replicate results
list below. The line charts showing the protein levels based on 2-DE
and Western blot results in the bottom of panel
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and HNRNPK genes expression status in RCC patients
seems contrary to common sense between metastasis and
prognosis. It must be mentioned that there are some
limitations about M0, M1 stages in oncomine database
without analyzing primary sites. Recent studies proposed
that survival from metastatic cancer depends on the pri-
mary sites, which can interpret this phenomenon [19].
Thus, though there are 8 genes overlapped, it was still
unable to discard any gene from these 9. But one thing is
certain, looking through these proteins’ functions, it is not
difficult to find, these proteins EEF1D, NDUFS1,
SLC9A3R1, EZR, HNRNPK, HSP90B1, VCP either
located at the membrane surface of organelle or were
closely related to energy metabolism. It has been impli-








































































Fold in western blot
B
Fig. 3 continued
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Immunohistochemistry results from patient samples
Subsequently, selected genes found to be differentially
expressed at the protein levels were validated further by
immunohistochemistry in RCC patient samples. We
checked all 26 proteins expression in our clinical samples.
Results showed that 8 genes detected their corresponding
proteins had strong signals. Interestingly, these 8 proteins
were covered by above nine. They are SLC9A3R1, VCP,
NDUFS1, EEF1D, HPCAL1, EZR, SET, HNRNPK with
low expression level in primary RCC but high in the bone
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Fig. 3 continued
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Protein identification and interactions
To classify identified proteins/genes, firstly we employed
the DAVID (biology informatics software) to assigned the
26 proteins/genes from 2-DE into ten different categories
in which the metabolism category was the largest and
together with the categories like transcription-related,
folding-associated proteins and cytoskeleton by which
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more than half proteins were covered (Supplementary 1A).
Secondly, we used STRING (http://www.string-db.org),
which is a database and a tool for predicting protein–pro-
tein interactions directly and indirectly. They are derived
from the following sources: previous knowledge, high-
throughput experiments, genomic context, conserved co-
expression. From STRING (Fig. 6a), the potential strong
connection can be seen, 10 necessary proteins/genes were
added into the network except for identified 8 proteins. The
official symbols and names of 18 genes corresponding to
all proteins was list on Supplementary 3 (Table 1). Fur-
thermore, the STRING analysis function showed these
MAPRE1
β-acn
B50          COPE               B52      MAPRE1                    B64      PSMB6 
β-acn
COPE





OS-RC-2                 OS-RC-2-BM5                OS-RC-2              OS-RC-2-BM5
















EZR          P=0.01697




































































































616 Clin Exp Metastasis (2015) 32:605–622
123
genes/proteins belong to different pathways: NDUFS1
NDUFS2 NDUFS3 is for oxidative phosphorylation pro-
cess; EEF1D led VCP and NSFL1C to regulate Golgi/
Endoplasmic Reticulum functions; SLC9A3R1 and EZR
are important proteins on the cell membrane and
cytoskeleton. The other proteins can be categorized into
calcium-binding protein, protein kinase, glutamate car-
boxypeptidase and regulation of translational initiation and
other functional proteins. Finally, we analyzed all these
genes in the ingenuity pathway analysis (IPA). The result
showed that oxidative phosphorylation, mitochondria dys-
function and granzyme A are the significantly activated
pathways (fold change over 1.5) (Fig. 6b), which caused
genes/proteins expression to change in RCC and increased
their ability of invasiveness and metastasis. Accordingly,
we summarized the possible mechanism that the primary
renal carcinoma turned into particular bone metastasis cells
in Fig. 6c.
Discussion
Recently, the mechanistic understanding of how mito-
chondrial dysfunction contributes to cell growth and
tumorigenesis is emerging. Most work focused on how
dysfunctional mitochondria modulate cell cycle, metabo-
lism, cell viability, gene expression and other established
aspects of cell growth, etc. However, mitochondrial
dynamics was modulated by key oncogenes and tumor
suppressors through some key signaling pathways and that
mitochondrial function vary between tumors and individ-
uals and even the significance of these events for cancer
have not yet been understood in detail [22]. Furthermore,
some biochemical and morphological events recognized as
characteristic features of apoptosis, the disruption of the
inner mitochondrial transmembrane potential (DWm) and
the release of cytochrome c into the cytoplasm were con-
sidered as early events [23]. Thus, it is not difficult to infer
the same events like interruption of inner mitochondrial
transmembrane potential, the release of cytochrome c and
reliance heavily on glycolysis to meet their metabolic
demands happened in carcinogenesis. Coincidentally and
interestingly, in our study, the 26 proteins differentiated
with 2-DE were classified into 10 different categories, the
metabolism category was the largest and covered more
than 50 % proteins. This point was confirmed by IPA
analysis as well (Supplementary 1B).
Next, we searched the public clinical microarray data-
base (ONCOMINE) to further validate the 2-DE results.
Results showed that 9 genes: SLC9A3R1, EEF1D,
HPLAL1, NDUFS1, SET, EZR, HNRNPK, VCP, and
HSP90B1 have close relation with RCC patients’ prognosis
or metastasis. Taking into account the uncertainty of some
data (set forth in Results) and more accurate identification
for the key proteins, we collected 57 clinical samples and
utilized the immunohistochemistry assay for all 26 pro-
teins. Fortunately for us, the 8 key genes/proteins emerged
significant positive signals in RCC osteolytic lesions,
which can match with the expected outcomes and really
covered by the above nine. So far, these 8 proteins/genes
were verified with 2-DE, Western blotting, the public
clinical microarray database and clinical patients’ sample
detection, which implied they are very critical in RCC bone
metastasis.
Subsequently, the 8 key genes functions were analyzed
with system biology approaches. The oxidative phospho-
rylation process, Golgi/Endoplasmic Reticulum functions
and some signal pathways related metabolism occupied the
main reasons. Analogous results were found in metastatic
breast cancer cells [24]. Thus, it had to make us convinced
the respiratory chain involved in the metabolic disorders
associated with the formation of bone metastasis in RCC
patients. In fact, the role of respiratory chain represents the
most basic mitochondrial functions. As core subunit of the
mitochondrial membrane respiratory chain NADH dehy-
drogenase (Complex I), NDUFS1, NDUFS2, NDUFS3
were believed to belong to the minimal assembly required
for catalysis. Deficiency and impairment of Complex I of
the respiratory chain can cause many mitochondrial dis-
eases [25–35]. Our studies showed NDUFS1 was overex-
pressed which directly reflected mitochondrial dysfunction.
Recent researches also demonstrated that mitochondrial
oxidative stress could actively promote tumor progression
and increase the metastatic potential of cancer cells [36]. In
view of these circumstances, it is reasonable to further
recognize mitochondrial dysfunction was involved in
skeleton metastasis of RCC.
In this research, VCP and EEF1D were found to express
abnormally as well. Both them functioned to co-regulated
Golgi-ER. VCP, the protein encoded by this gene belongs
to a family that includes putative ATP-binding proteins.
Likewise, EEF1D protein is responsible for the enzymatic
delivery and it is a subunit of the elongation factor-1
bFig. 4 The prognostic signature on Kaplan–Meier curve showing 9
out of 26 genes significantly affected survival time of RCC patients
when their expressions were high or low. These data originated in
public clinical dataset. Gene expression was estimated by average as
standard, expression higher than it was called high expression and the
opposite ones named low expression. The K–M curves showed that
patients with EEF1D, NDUFS1, HPCAL1, EZR, SLC9A3R1,
HSP90B1 genes low expression survived longer than those with high
expression. Conversely, the patients with high level VCP, SET and
HNRNPK genes had a better prognosis than cases with low
expression (marked with circle). Red line represents high expression
and black line means low expression. P value is measured with log
rank-test. (Color figure online)































































Fig. 5 Results of immunohistochemistry DAB staining showing 8
genes/proteins expressed in samples primary RCC and secondary
bone lesions of RCC patients. The eight positive results involved
SLC9A3R1, NDUFS1, EEF1D, HPCAL1, VCP, SET, HNRNPK and
EZR proteins. All of them were overexpressed in skeletal lesions of
RCC patients comparing with primary RCC. Scale bar 20 lm
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complex as well. They has been implicated in a number of
cellular events including regulation of mitochondria func-
tion [37–40].
Generally, reassembling of cytoskeletal proteins is an
important feature of morphological changes during
metastasis. Therefore, it is not surprising that SLC9A3R1
and EZR differentially regulated proteins, which belong to
components of microfilaments, microtubuli and interme-
diary filaments [41, 42]. They are in the maintenance of
cell architecture, adhesion, migration, differentiation,
division, and organelle transport. The SLC9A3R1 protein
localizes to microvilli, filopodia and membrane ruffles. It
regulates and interacts with various proteins. Additionally,
SLC9A3R1 also functions as linkers between cytoskeletal
proteins and integral membrane [43]. EZR which also
locates in microvilli, as cytoplasmic peripheral membrane
protein, functions as an intermediate between the actin
cytoskeleton and the plasma membrane. Particularly, it
plays a key role in cell surface structure organization,
adhesion and migration, and it has been implicated in
various human cancers [44, 45]. The comparison of the
results showed the group of up-regulated cytoskeleton
proteins regulated concordantly mitochondria functions.
As we all known, cancer cells strongly up-regulate
glucose uptake and glycolysis to give rise to increased
yield of intermediate glycolytic metabolites and the end
product pyruvate. At the same time, mitochondrial dys-
function precedes an aerobic glycolysis and can cause
cancer cells genome instability and increased entropy and
finally a series of cellular functions disorders [46, 47]. In
addition, mitochondrial dysfunction leading to mtDNA
mutations can enhance cancer metastasis through increased
ROS and apoptotic resistance [48, 49].
Based on these evidence reviewed above, we depicted
the potential mechanism in Fig. 6c. It showed how the
normal cell changed to malignant behavior even metastasis
potential: under unspecific carcinogenesis conditions like
carcinogens, inflammation, radiation, viral infections,
intermittent hypoxia which damaged a cell’s oxidative
phosphorylation, the structure and function of mitochon-
dria were damaged thus activating a respiratory chain
changes (Complex I, II, III, IV) and also cytochrome c
release. When the mitochondrial dysfunction persists, it
produces genome instability (mtDNA mutation) and further
lead to malignant transformation (metastasis) via increased
ROS and apoptotic resistance. Hence, the impaired energy
metabolism can be linked to invasion and metastasis if this
impairment occurs in cells. [47].
Overall, in this paper, we elucidated protein profiles of
OS-RC-2-P and OS-RC-2-BM5 cells. A number of proteins
were altered in abundance and part of them was identified
successfully. These proteins were involved in multiple
functions and participated in a variety of biological pro-
cesses in which dysregulation of mitochondrial function in
RCC cells can push the formation of overt bone metastasis
in clinic and therefore it is necessary for mitochondrial
dysfunction to be taken a continued consideration as a
therapeutic target on RCC bone metastasis in future
research. Most importantly and hopefully, RCC patients
can benefit from developing new antioxidant-based anti-
cancer therapy to eliminate mitochondrial dysfunction and
prevent or even reverse the formation of bone metastasis.
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